Dyne Therapeutics
Waltham, US · 3 known investors
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform. The company focuses on discovery, clinical development, and commercialization of treatments for rare genetic disorders.
BiotechMedical Devices
Investors · 3
In the news
- Intellectiaintellectia.ai · 2026
- Dyne Therapeutics stock initiated at buy by TD Cowen on platform By Investing.cominvesting.com · 2026
- Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain?sahmcapital.com · 2026
- Dyne Therapeutics Series B financing - CureDuchennecureduchenne.org · 2020
- Dyne Therapeutics Raises $115M in Equity Financing - FinSMEsfinsmes.com · 2020
- Dyne Therapeutics Raises $50M in Series A Funding - FinSMEsfinsmes.com · 2019